- Published at
- by themarketherald.com.au
mixed
mixed
ASX Market Close: IT stocks lead index higher | May 15, 2025
The ASX200 closed up 0.22% at 8,297 points. IT was the best…
News for Amplia Therapeutics Limited (ATX.AX)
- Published at
- by themarketherald.com.au
positivepositiveAmplia pops 40% on liquidity surge as chemo combo proves successful
Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes...- Published at
- by smallcaps.com.au
negativenegativeAmplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib
Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate- Published at
- by investing.com
negativenegativeFDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER By Investing.com
FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER- Published at
- by themarketherald.com.au
mixedmixedASX Market Close: Index up again, Min Res gains on job loss plan | August 7, 2024
The ASX200 made a small recovery today after the torrid start to the week, closing up a quarter of a per cent to about 7700 points.- Published at
- by themarketherald.com.au
positivepositiveAmplia moves to next stage of cancer drug trial for narmafotinib
Amplia Therapeutics Ltd is set to move further through its Phase 2a trial for cancer drug narmafotinib, with four patients showing a response.- Published at
- by themarketherald.com.au
negativenegativeAmplia enrols new patients to progress testing for pancreatic cancer drug
Amplia Therapeutics Ltd has enrolled a new group of patients to test the efficacy of its drug narmafotinib in treatment of pancreatic cancer.- Published at
- by themarketherald.com.au
neutralneutralAmplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful completion of phase 1b of the trial- Published at
- by themarketherald.com.au
positivepositiveAmplia Therapeutics mints $2.4m R&D tax benefit
Amplia Therapeutics (ASX:ATX) has confirmed a $2.4 million R&D tax benefit on the back of research using the company's FAK inhibitors.- Published at
- by prnewswire.com
negativenegativeAMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic...- Published at
- by themarketherald.com.au
mixedmixedTMH Spotlight: OncoSil Medical (ASX:OSL) treats first patient in Italy, Iceni Gold (ASX:ICL) strikes high grade gold at Guyer
The ASX opened lower this morning, while majority of the sectors dragged.- Published at
- by themarketherald.com.au
positivepositiveAmplia Therapeutics (ASX:ATX) receives grant funding to support research collaboration with CSIRO
Amplia Therapeutics (ASX:ATX) has secured grant funding to support research collaboration with Australia's national science agency, CSIRO.- Published at
- by stockhead.com.au
mixedmixedCheck Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.- Published at
- by stockhead.com.au
mixedmixedASX Small Caps Lunch Wrap: Who else is trying to dance on the ceiling this morning?
The ASX has dipped 0.2% this morning as the US braces for CPI data, while Magnum's gone flying thanks to a huge offtake deal with Mitsubishi.- Published at
- by stockhead.com.au
mixedmixedCheck Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales
The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.PSQ.AXPGC.AXOSX.AXOPT.AXOPTNOXOFNOX.AXIUGNFIMU.AXGSS.AXCYP.AXCKDXFBPH.AXATX.AX4DX.AXZNO.AXSCU.AXRSH.AXPXSLYPXS.AXPAB.AXOCC.AXNC6.AXKZA.AXKMLXFIHL.AXIDT.AXFDMDFDVL.AXCMP.AXBITRFBIT.AXARUXFAMT.AXACR.AX1AD.AXZLD.AXVTG.AXVLS.AXUBI.AXTD1.AXSOMNFSOM.AXRNO.AXRHY.AXRHT.AXRGS.AXRAC.AXPYC.AXPNV.AXPCK.AXPBP.AXOVN.AXOSL.AXONE.AXOIL.AXNYR.AXNXSCFNXS.AXMXC.AXMX1.AXMVF.AXMEM.AXMEB.AXMDR.AXMDC.AXMDBIFLBT.AXIVX.AXIPDQFIPD.AXIMRNWIMRNIMM.AXIMC.AXICR.AXHCT.AXGTG.AXGLH.AXEYE.AXDXB.AXCSL.AXCPH.AXCGS.AXCAN.AXCALZFCAJ.AXBXN.AXBWXXFBWX.AXBNOEFBNO.AXAT1.AXARX.AXAMDHFALC.AXADR.AXADO.AX1ST.AX- Published at
- by stockhead.com.au
mixedmixedCheck Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger
Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.TD1.AXRGS.AXRAC.AXFFC.AXEZL.AXPYC.AXPAB.AXOPT.AXOPTMX1.AXCMP.AXCKDXFAMT.AXVTG.AXVLS.AXSOMNFSOM.AXSCU.AXRNO.AXRHT.AXPXSLYPXS.AXPSQ.AXPNV.AXPGC.AXPBP.AXONE.AXOCC.AXNYR.AXNC6.AXMVF.AXMEM.AXMEB.AXMDBIFLBT.AXIVX.AXIPDQFIPD.AXIMM.AXHCT.AXGTG.AXGSS.AXEYE.AXCGS.AXCAN.AXCALZFCAJ.AXBXN.AXBWXXFBWX.AXBNOEFBNO.AXATX.AXARUXFAMDHFADR.AXACR.AX- Published at
- by stockhead.com.au
mixedmixedCheck Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.PYC.AXPSQ.AXPGC.AXMSB.AXKZA.AXEYE.AXDVL.AXCAN.AXBXN.AXBNOEFBNO.AXADO.AXSOMNFSOM.AXRSH.AXRHT.AXRGS.AXOSX.AXOSL.AXONE.AXOIL.AXNXSCFNXS.AXMEB.AXMDC.AXMDBIFKMLXFIVX.AXIUGNFIMU.AXIDT.AXGLH.AXCYP.AXCMP.AXCAJ.AXAT1.AXADR.AX1ST.AXZNO.AXZLD.AXVTG.AXVLS.AXUBI.AXTD1.AXSCU.AXRNO.AXRHY.AXRAC.AXPXSLYPXS.AXPNV.AXPCK.AXPBP.AXPAB.AXOVN.AXOPT.AXOPTOCC.AXNYR.AXNOXOFNOX.AXNC6.AXMXC.AXMX1.AXMVF.AXMEM.AXMDR.AXLBT.AXIPDQFIPD.AXIMRNWIMRNIMM.AXIMC.AXIHL.AXICR.AXHCT.AXGTG.AXGSS.AXFDMDFDXB.AXCPH.AXCKDXFCGS.AXCALZFBWXXFBWX.AXBPH.AXBITRFBIT.AXATX.AXARX.AXARUXFAMT.AXAMDHFALC.AXACR.AX4DX.AX1AD.AX- Published at
- by stockhead.com.au
mixedmixedCheck Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.ZNO.AXZLD.AXRAP.AXPSQ.AXPIQ.AXPBP.AXPAA.AXMXC.AXIPDQFIPD.AXIDT.AXGLH.AXCGS.AXBXN.AX1AD.AXSOMNFSOM.AXSHL.AXRSH.AXRGS.AXPGC.AXPCK.AXOVN.AXOSX.AXOSL.AXOIL.AXNYR.AXNXSCFNXS.AXMX1.AXMDC.AXLBT.AXKZIAKZA.AXKMLXFIVX.AXIMMPIMM.AXIHL.AXGSS.AXFDMDFDVL.AXCYP.AXCPH.AXCAN.AXBWXXFBWX.AXBPH.AXBNOEFBNO.AXBITRFBIT.AXAT1.AXARX.AXAKU.TOAKUADR.AX4DX.AX1ST.AXVTG.AXVLS.AXUBI.AXSCU.AXRNO.AXRHY.AXRHT.AXRAC.AXPYC.AXPXSLYPXS.AXPNV.AXPAB.AXOPT.AXOPTONE.AXOCC.AXNOXOFNOX.AXNC6.AXMVF.AXMEM.AXMEB.AXMDR.AXMDBIFIUGNFIMU.AXIMRNWIMRNIMC.AXICR.AXHCT.AXEYE.AXDXB.AXCMP.AXCKDXFCALZFCAJ.AXATX.AXARUXFAMT.AXAMDHFALC.AXADO.AXACR.AX- Published at
- by stockhead.com.au
mixedmixedCheck Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half
Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.TD1.AXRSH.AXPCK.AXMX1.AXKMLXFDVL.AXCAJ.AXBNOEFBNO.AXARX.AXADR.AX1ST.AXZNO.AXRHY.AXRAC.AXPYC.AXPSQ.AXPGC.AXOVN.AXOSX.AXONE.AXOCC.AXNOXOFNOX.AXNC6.AXMDC.AXKZA.AXIPDQFIPD.AXIDT.AXGTG.AXCYP.AXCPH.AXCAN.AXBXN.AXBWXXFBWX.AXBPH.AXBITRFBIT.AXATX.AXZLD.AXVTG.AXVLS.AXUBI.AXSOMNFSOM.AXSCU.AXRNO.AXRHT.AXRGS.AXPXSLYPXS.AXPNV.AXPBP.AXPAB.AXOSL.AXOPT.AXOPTOIL.AXNYR.AXNXSCFNXS.AXMXC.AXMVF.AXMEM.AXMDR.AXLBT.AXIVX.AXIUGNFIMU.AXIMRNWIMRNIMM.AXIMC.AXIHL.AXICR.AXHCT.AXGSS.AXGLH.AXFDMDFEYE.AXDXB.AXCMP.AXCKDXFCGS.AXCALZFAT1.AXARUXFAMT.AXAMDHFALC.AXADO.AXACR.AX4DX.AX1AD.AX- Published at
- by prnewswire.com
mixedmixedPropulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
/PRNewswire/ -- DelveInsight's 'Pancreatic Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...